Torthaí cuardaigh - Kathrine C. Fernandez

  • 1 - 6 toradh as 6 á dtaispeáint
Beachtaigh na torthaí
  1. 1
    Validation of the Revised Screener and Opioid Assessment for Patients With Pain (SOAPP-R)

    Validation of the Revised Screener and Opioid Assessment for Patients With Pain (SOAPP-R) de réir Stephen F. Butler, Kathrine C. Fernandez, Christine Benoit, Simon H. Budman, Robert N. Jamison

    Foilsithe / Cruthaithe 2008
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    Cross-Validation of a Screener to Predict Opioid Misuse in Chronic Pain Patients (SOAPP-R)

    Cross-Validation of a Screener to Predict Opioid Misuse in Chronic Pain Patients (SOAPP-R) de réir Stephen F. Butler, Simon H. Budman, Kathrine C. Fernandez, Gilbert J. Fanciullo, Robert N. Jamison

    Foilsithe / Cruthaithe 2009
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    Development and validation of the Current Opioid Misuse Measure

    Development and validation of the Current Opioid Misuse Measure de réir Stephen F. Butler, Simon H. Budman, Kathrine C. Fernandez, Brian Houle, Christine Benoit, Nathaniel P. Katz, Robert N. Jamison

    Foilsithe / Cruthaithe 2007
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    Does Report of Craving Opioid Medication Predict Aberrant Drug Behavior Among Chronic Pain Patients?

    Does Report of Craving Opioid Medication Predict Aberrant Drug Behavior Among Chronic Pain Patients? de réir Ajay D. Wasan, Stephen F. Butler, Simon H. Budman, Kathrine C. Fernandez, Roger D. Weiss, Shelly F. Greenfield, Robert N. Jamison

    Foilsithe / Cruthaithe 2009
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR <i>BRAF</i> V600E-mutant mCRC

    SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR <i>BRAF</i> V600E-mutant mCRC de réir Elena Élez, Scott Kopetz, Josep Tabernero, Tanios Bekaii‐Saab, Julien Taı̈eb, Takayuki Yoshino, Gulam A. Manji, Kathrine C. Fernandez, Antonello Abbattista, Xiaosong Zhang, Van K. Morris

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  6. 6
    Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial

    Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial de réir Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, Mayer Fishman, David F. McDermott, Daniel C. Cho, Ulka N. Vaishampayan, Saby George, Thomas Olencki, Jamal Tarazi, Brad Rosbrook, Kathrine C. Fernandez, Mariajosé Lechuga, Toni K. Choueiri

    Foilsithe / Cruthaithe 2018
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: